Greece Pharmaceuticals and Healthcare Report Q2 2008

Publication Date	April 2008
Publisher	Business Monitor
Product Type	Report
Pages	68
ISBN Number	not applicable
Product Code	BMI01646

Price

£425.00
approximately: $835 | €540

PDF immediate delivery

Order above formats by FAX

Summary

Greece has a highly developed pharmaceutical market, typified by low generic penetration, the presence of many international drugmakers and a mature intellectual property (IP) environment. However, there are signs that suggest the market has some evolving to do. A change in the reimbursement system in the late 1990s failed to bring down expenditure and the country is still tainted by a parallel importation court case. Accordingly, BMI is projecting 3-4% growth to 2012, when the overall pharmaceutical market will be worth US$6.85bn.

Compared to its Central and Eastern European (CEE) neighbours, Greece's pharmaceutical sector is somewhat of an anomaly, being more akin to Western Europe. Generic drugs only account for 11.5% of the market and patented products make up 81.1% of sales. The over-the-counter (OTC) sub-sector - at 7.9% of the market - is under-developed, but this should expand in the medium term, following the removal of such products from the reimbursement scheme.

In the Q208 Pharmaceutical and Healthcare BMI Business Environment Ranking for the CEE region, Greece is still in pole position out of the 15 regional markets surveyed. The country's pharmaceutical rating is 63, four points higher than the second-ranked country, the Czech Republic, and unchanged from the previous quarter.

The main development of the past few months has been the expansionist activities of local firm Alapis.

Following the purchases of domestic rival Farmalex in mid-2007, Alapis acquired a 49% stake in KP Marinopoulos, one of the largest local pharmaceutical wholesalers, during Q407. Then, in February 2008, Alapis bought Labomed, the Athens-based company specialising in the trade of medical, laboratory and diagnostic equipment, for EUR2mn (US$2.9mn). Alapis acquired another local company, Lamda Applied Pharmaceuticals Laboratory for Applied Research, for EUR475,000 (US$695,000).

A human papillomavirus vaccine (either Merck & Co's Gardasil or GlaxoSmithKline's Cervarix) was added to the national immunisation calendar in October 2007. At the time, Belgium Denmark and Spain were the only other European nations that had decided to do likewise.

Content

Executive Summary
Greece Pharmaceuticals And Healthcare Industry SWOT
Greece Political SWOT
Greece Economic SWOT
Greece Business Environment SWOT
Pharmaceutical Business Environment Rating
- Table: Central And Eastern Europe Pharmaceutical And Healthcare Business Environment Rankings
Limits Of Potential Returns
Risks To Realisation Of Returns
Greece - Market Summary
Regulatory Regime
Intellectual Property Regime
Pricing Regime
- Table: Pharmaceutical Pricing In Greece
Reimbursement Regime
Parallel Trade
Industry Developments
Health Profile
Healthcare System
Secondary Care
Healthcare Expenditure
Healthcare Reforms
Pharmaceutical Industry
Wholesale And Retail Sectors
Recent Pharmaceutical Industry Developments
Industry Forecast Scenario
Overall Market Forecast
- Table: Greece's Drug Market Indicators, 2006-2012
Key Growth Factors - Industry
- Table: Greece's Health Expenditure Indicators, 2006-2012
Key Growth Factors - Macroeconomic
A Four Percent Zenith
- Table: ECONOMIC ACTIVITY
Prescription Market Forecast
- Table: Greece's Prescription Drugs Market Indicators, 2006-2012 (US$mn unless otherwise stated)
OTC Market Forecast
- Table: Greece's OTC Drugs Market Indicators, 2006-2012 (US$mn unless otherwise stated)
Generics And Patented Market Forecasts
- Table: Greece's Generics And Patented Market Indicators, 2006-2012
Export/Import Forecasts
- Table: Greece's Pharmaceuticals Exports And Imports Indicators, 2006-2012 (US$mn)
Other Healthcare Data Forecasts
- Table: Greece Other Healthcare Data Forecasts
Key Risks To BMI Forecasts
Competitive Landscape
- Table Top 10 Best-Selling Pharmaceuticals In Greece, 2
- Table: Top 10 Pharmaceutical Companies In Greece By Sales, 2006
Company Monitor
Multinational Company Profiles
GlaxoSmithKline
Pfizer
Novartis
Sanofi-Aventis
Merck & Co
Abbott Laboratories
Indigenous Company Profiles
Vianex
Lavipharm
Gerolymatos SA
Genesis Pharma
Genepharm
Pharmathen Pharmaceuticals
Kleva
BMI Forecast Modelling
How We Generate Our Industry Forecasts
Pharmaceutical Industry
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
Weighting
- Table: Weighting Of Components
Sources